Clinical Trial Update: A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 clinical trial results for baricitinib in participants with severe or very severe alopecia areata have been completed and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alopecia Areata

Drugs mentioned

• Baricitinib (baricitinib)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Alopecia Areata | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2025-10-01